Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
26 Cards in this Set
- Front
- Back
187. What are the two uricosuric drugs?
|
1. Probenecid
2. Sulphinpyrazone |
|
188. MOA of allopurinol?
|
a. Allopurinol is a xanthine oxidase inhibitor-it decreases uric acid synthesis.
b. Use once daily dosing. It is well-tolerated. |
|
189. Contraindication for allopurinol?
|
a. Never give allopurinol for acute gout-it makes it worse.
|
|
190. How should you decide whether to use a uricosuric agent (Probenecid or sulfinpyrazone) or allopurinol?
|
a. The choice depends on how much uric acid is excreted in the urine in a 24-hour period.
b. If the uric acid excretion is less than 800 mg per day, this indicates under excretion of urate and a uricosuric agent (Probenecid or sulfinpyrazone) should be used. c. If a 24-hour urine uric acid is greater than 800 mg per day, this indicates overproduction and allopurinol may be used. |
|
191. Contraindications for using uricosuric agents (Probenecid and sulfinpyrazone)?
|
a. Use them only in patients with normal renal function.
b. They are contraindicated if the patient has a history of renal stones |
|
192. What 2 medications should be avoided with acute gout?
|
a. Aspirin- it can aggravate the problem.
b. Acetaminophen-has no anti-inflammatory properties. |
|
193. What does pseudogout represent a deposition of?
|
a. Calcium pyrophosphate crystals in joints, leading to inflammation.
|
|
194. Risk factors for pseudogout (calcium pyrophosphate disease)?
|
a. Deposition increases with age and with OA of the joints. Therefore, pseudogout is common in elderly patients with degenerative joint disease.
b. Other conditions that may increase crystal deposition include: 1. Hemochromatosis 2. Hyperparathyroidism 3. Hypothyroidism 4. Bartter’s syndrome |
|
195. Clinical features of pseudogout (calcium pyrophosphate deposition disease)?
|
a. Most commonly affects knees and wrists.
b. Is classically monoarticular, the can be polyarticular as well. |
|
196. What is required for definitive diagnosis of pseudogout?
|
a. Joints aspirate
b. it demonstrates weekly positive birefringent, rod shaped and rhomboid crystals in synovial fluid (calcium pyrophosphate crystals). |
|
197. What may radiographs demonstrate with pseudogout?
|
a. Chondrocalcinosis (cartilage calcification)
|
|
198. Treatment of pseudogout?
|
a. Treat the underlying disorder (if identified)
b. Symptomatic management is similar to that for gout (NSAIDs, colchicine, intra-articular steroid injections) c. Total joint replacement is appropriate if symptoms are debilitating. |
|
199. Common locations for OA?
|
a. Weight-bearing joints (knees, hips, lumbar/cervical spine), hands.
|
|
200. Common locations for RA?
|
a. Hands (PIP, MCP)
b. Wrists c. Ankles d. Knees |
|
201. Common locations for Gouty Arthritis?
|
a. Great toe
b. Ankles c. Knees d. Elbows |
|
202. Presence of inflammation w/OA?
|
a. NO
|
|
203. Presence of inflammation w/RA?
|
a. Yes
|
|
204. Presence of inflammation w/Gouty Arthritis?
|
a. Yes
|
|
205. Radiographic changes w/OA?
|
a. Narrowed joint space
b. Osteophytes c. Subchondral sclerosis d. Subchondral cysts |
|
206. Radiographic changes w/RA?
|
a. Narrowed joint space
b. Bony erosions |
|
207. Radiographic changes w/Gouty Arthritis?
|
a. Punched-out erosions w/overhanging rim of cortical bone.
|
|
208. Laboratory changes w/OA?
|
a. None
|
|
209. Laboratory changes w/RA?
|
a. Elevated ESR
b. RF c. Anaemia |
|
210. Laboratory changes w/Gouty Arthritis?
|
a. Crystals
|
|
211. Systemic findings in OA vs. RA?
|
a. No systemic findings in OA
b. RA has extra-articular manifestations, ulnar deviation, swan-neck and boutonniere deformity. |
|
212. Extra-articular findings w/Gouty Arthritis?
|
a. Tophi
b. Nephrolithiasis. |